Rollout of disease-modifying CFTR modulators to the vast majority of people with CF may now place further emphasis on animal models to provide a means of investigating baseline differences in uncorrected, CFTR-deficient immune cells with the aim of developing novel strategies to combat chronic inflammation alongside modulator therapies and the standard treatment regimen [4]. Here, CFTR is linked to cystic fibrosis.